Mutant calreticulin: When a chaperone becomes intrusive

Blood

Volumn 127, Issue 10, 2016, Pages 1219-1221

  Cazzola, Mario ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; THROMBOPOIETIN RECEPTOR; LIM PROTEIN; MUSCLE PROTEIN; TUMOR PROTEIN;

BONE MARROW CELL; CALCIUM HOMEOSTASIS; CARBOXY TERMINAL SEQUENCE; CELL GROWTH; GLYCOSYLATION; HUMAN; INDEL MUTATION; MEGAKARYOPOIESIS; MOLECULAR PATHOLOGY; MYELOPROLIFERATIVE DISORDER; NONHUMAN; NOTE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THROMBOCYTOPOIESIS; THROMBOCYTOSIS; ANIMAL; HEMATOLOGIC DISEASE; MEGAKARYOCYTE; METABOLISM; MUTATION; MYELOID METAPLASIA;

ANIMALS; CALRETICULIN; HEMATOLOGIC NEOPLASMS; HUMANS; INDEL MUTATION; LIM DOMAIN PROTEINS; MEGAKARYOCYTES; MUSCLE PROTEINS; MUTATION; MYELOPROLIFERATIVE DISORDERS; NEOPLASM PROTEINS; PRIMARY MYELOFIBROSIS; RECEPTORS, THROMBOPOIETIN; THROMBOCYTOSIS;

EID: 84960926473     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-01-694182     Document Type: Note

References (13)

1. Marty C, Pecquet C, Nivarthi H, et al. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. Blood. 2016;127(10):1317-1324.
2. Chachoua I, Pecquet C, El-Khoury M, et al. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. Blood. 2016; 127(10):1325-1335.
3. Araki M, Yang Y, Masubuchi N, et al. Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms. Blood. 2016;127(10):1307-1316.
4. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379-2390.
5. Wang WA, Groenendyk J, Michalak M. Calreticulin signaling in health and disease. Int J Biochem Cell Biol. 2012;44(6):842-846.
6. Rumi E, Pietra D, Ferretti V, et al; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014;123(10):1544-1551.
7. Rumi E, Pietra D, Pascutto C, et al; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood. 2014;124 7):1062-1069.
8. Pietra D, Rumi E, Ferretti VV, et al. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia. 2016;30(2):431-438.
9. Elf S, Abdelfattah N, Chen E, et al. Physical interaction between mutant calreticulin and the thrombopoietin receptor is required for hematopoietic transformation [abstract]. Blood. 2015;126(23). Abstract LBA-4.
10. Qian H, Buza-Vidas N, Hyland CD, et al. Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells. Cell Stem Cell. 2007;1(6): 671-684.
11. Yoshihara H, Arai F, Hosokawa K, et al. Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche. Cell Stem Cell. 2007;1(6):685-697.
12. Verger E, Cassinat B, Chauveau A, et al. Clinical and molecular response to interferon-a therapy in essential thrombocythemia patients with CALR mutations. Blood. 2015;126(24):2585-2591.
13. Jeremy Wen Q, Yang Q, Goldenson B, et al. Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. Nat Med. 2015;21(12):1473-1480.